Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report
Key Takeaways from the Hemophilia Pipeline Report
In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector.
In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.
In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies
Hemophilia Emerging Drugs Profile
SerpinPC: Centessa Pharmaceuticals
SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.
Fitusiran: Alnylam Pharmaceuticals
Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.
ASC 618: ASC Therapeutics
ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.
The Hemophilia Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment.
Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market.
Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs
Hemophilia Companies
Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives
Scope of the Hemophilia Pipeline Report
Coverage- Global
Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Hemophilia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Fitusiran: Alnylam Pharmaceuticals
Mid Stage Products (Phase II)
SerpinPC: Centessa Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Preclinical and Discovery Stage Products
Drug name: Company Name
Inactive Products
Hemophilia Key Companies
Hemophilia Key Products
Hemophilia- Unmet Needs
Hemophilia- Market Drivers and Barriers
Hemophilia- Future Perspectives and Conclusion
Hemophilia Analyst Views
Hemophilia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Paramount Global Reports Strong Q2 2025 Earnings
Paramount Global ( (PARA)) has released its Q2 earnings. Here is a breakdown of the information Paramount Global presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Paramount Global is a leading global media and entertainment company known for its extensive portfolio of iconic brands, including CBS, Paramount Pictures, and Paramount+, offering a wide range of content and streaming services. In its latest earnings report for Q2 2025, Paramount Global highlighted its continued transformation into a streaming-first company, with direct-to-consumer (DTC) revenue growing by 15% year-over-year, driven by the strong performance of Paramount+. The company's total revenue increased by 1% compared to the previous year, with notable growth in affiliate and subscription revenue. Paramount+ saw a 23% increase in total revenue and a 24% rise in subscription revenue, reflecting improved watch time and reduced churn. Despite a 6% decline in TV media revenue, the company achieved significant milestones in its content offerings, with CBS maintaining its position as the most-watched broadcast network in primetime for the 17th consecutive season. Paramount Pictures also reported a successful quarter, with the global premiere of 'Mission: Impossible – The Final Reckoning' setting a franchise record for the biggest global opening. Looking ahead, Paramount Global's management remains optimistic about the company's growth prospects, emphasizing the strength of its content strategy and the ongoing expansion of its streaming services.
Globe and Mail
2 hours ago
- Globe and Mail
Comcast Reports Strong Q2 2025 Earnings Growth
Comcast Corp ( (CMCSA)) has released its Q2 earnings. Here is a breakdown of the information Comcast Corp presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Comcast Corporation is a global media and technology company that provides broadband, wireless, and video services through brands like Xfinity and Sky, and produces and distributes content via NBC, Universal, and Peacock, among others. In its second-quarter earnings report for 2025, Comcast Corporation announced a 2.1% increase in revenue to $30.3 billion and a significant rise in net income attributable to Comcast to $11.1 billion, largely due to a $9.4 billion gain from the sale of its interest in Hulu. The company also reported a 3.3% increase in adjusted earnings per share to $1.25 and generated $4.5 billion in free cash flow. Comcast's wireless business achieved record growth, adding 378,000 lines, and its theme parks segment saw a revenue increase of 18.9%, driven by the opening of Epic Universe. The company's media segment also performed well, with Peacock revenue up 18%. Despite a decrease in adjusted net income by 1.7%, Comcast returned $2.9 billion to shareholders through dividends and share repurchases. Looking ahead, Comcast remains confident in its strategic focus and capital allocation, positioning itself well for future growth with plans to expand its content offerings, including NBA coverage on Peacock.
Globe and Mail
2 hours ago
- Globe and Mail
AbbVie Reports Strong Q2 2025 Financial Results
Abbvie ( (ABBV)) has released its Q2 earnings. Here is a breakdown of the information Abbvie presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie Inc. is a global biopharmaceutical company that focuses on discovering and delivering innovative medicines in key therapeutic areas such as immunology, neuroscience, oncology, and eye care, alongside its Allergan Aesthetics portfolio. In the second quarter of 2025, AbbVie reported a strong financial performance with an increase in net revenues and adjusted earnings per share, highlighting the company's diversified growth platform and strategic investments in innovation. Key financial metrics from the quarter include a 6.6% increase in net revenues to $15.423 billion, driven by significant growth in the immunology and neuroscience portfolios. Skyrizi and Rinvoq showed substantial revenue increases of 62.2% and 41.8%, respectively, while the neuroscience portfolio grew by 24.2%. However, the aesthetics portfolio saw a decline of 8.1% in revenues. AbbVie also announced several strategic advancements, including FDA approvals for new treatments and positive clinical trial results, which bolster its pipeline and future growth prospects. The company has raised its full-year 2025 adjusted diluted EPS guidance, reflecting confidence in continued momentum. Looking ahead, AbbVie remains optimistic about its growth trajectory, supported by its robust pipeline and strategic initiatives, as it continues to focus on delivering innovative solutions to address significant health challenges.
